KRM Ayurveda IPO Live Updates: Day 2 GMP & Subscription Details

The KRM Ayurveda IPO GMP stands at ₹12 as of 22 January 2026, indicating positive market sentiment. The IPO is a book-building issue worth ₹77.49 crore and consists entirely of a fresh issue of 0.57 crore shares.

The price band is set at ₹128 to ₹135 per share with a face value of ₹10. Shares are expected to list on NSE SME on 29 January 2026. Retail investors can apply for a minimum of 2 lots (2,000 shares), requiring an investment of ₹2,70,000.

With a GMP of ₹12, the estimated listing price is around ₹147 per share, suggesting a potential listing gain of nearly 9%. Earlier GMP levels were higher, but recent trends show some moderation.

As of Day 2, the IPO has been subscribed 1.61 times. Retail investors and NIIs have each subscribed 2.25 times, while QIB participation remains nil so far. The steady subscription indicates healthy investor interest ahead of the listing.

KRM Ayurveda Limited, incorporated in 2019, operates Ayurvedic hospitals and clinics across India and also offers telemedicine services internationally. The company manufactures Ayurvedic medicines, herbal remedies, supplements, and wellness products, supported by in-house Panchakarma, pharmacy, yoga, and consultation facilities.

Financially, the company reported strong growth in FY25, with revenue rising 13.88% to ₹76.95 crore and profit after tax jumping 254.83% to ₹12.10 crore.

The IPO proceeds will be used for setting up telemedicine facilities, purchasing CRM and IT infrastructure, meeting working capital needs, repaying loans, strengthening human resources, and general corporate purposes.

Overall, KRM Ayurveda IPO has received a positive response so far, supported by decent GMP, strong retail participation, and improving financial performance.